Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma-Reference-Cited by-同舟云学术

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Published:2015-12-10 Issue:4 Volume:7 Page:4093-4109
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Patwardhan Parag P.¹,Ivy Kathryn S.¹,Musi Elgilda¹,de Stanchina Elisa²,Schwartz Gary K.¹³

Affiliation:

1. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

2. Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3. Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?;Cell Communication and Signaling;2024-09-09

2. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

3. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer;Investigational New Drugs;2024-08-21

4. The pro-tumoral and anti-tumoral roles of EphA4 on T regulatory cells and tumor associated macrophages during HNSCC tumor progression;2024-08-13

5. Aptamer-Based Enforced Phosphatase-Recruiting Chimeras Inhibit Receptor Tyrosine Kinase Signal Transduction;Journal of the American Chemical Society;2024-08-01